

Health Connects Us All

AstraZeneca Annual Report 2010-11



AstraZeneca


Health is something that connects us all

AstraZeneca's mission is to make a meaningful difference to the world's health. It works closely with governments and regulators, it's partners in industry and academia, and doctors. Through its activities it touches a great number of people's lives and we at AstraZeneca are acutely conscious of our responsibility to patients and society in general.



Contents

5	Notice
10	Directors' Report
19	Management Discussion & Analysis Report
21	Report on Corporate Governance
36	Auditors' Report
40	Balance Sheet
41	Profit and Loss Account
42	Cash Flow Statement
56	Notes to the Accounts
78	Ten Years Summary
	Proxy/Attendance Slip
	NECS Mandate Form



AstraZeneca Pharma India Limited

Board of Directors

Mr. D. E. Udawadia, *Chairman*
 Mr. K. S. Shah
 Mr. Ian Brimicombe
 Mr. Bhasker V. Iyer (Till February 23, 2010)
 Mr. Francis McNamara III (Till September 30, 2010)
 Mr. Luigi Felice La Corte (Effective March 25, 2010)
 Mr. Anandh Balasundaram, *Managing Director*

Auditors

BSR & Co., Bangalore

Legal Advisors

Udawadia & Udeshi, Mumbai

Bankers

The Hongkong and Shanghai
 Banking Corporation Limited

Corporate and Registered Office

'Avishkar', Off Bellary Road
 Hebbal, Bangalore 560 024

Factory

12th Mile on Bellary Road
 Kattignenahalli Village, Yelahanka
 Bangalore 560 063

Sales Outlets

Ahmedabad, Bangalore*, Chennai, Cuttack,
 Dehradun, Delhi*, Ghaziabad, Guwahati,
 Secunderabad, Indore, Jaipur, Kochi, Kolkata
 Lucknow, Mumbai, Patna, Ranchi, Vijayawada,
 Chandigarh, Panchkula and Zirakhpur.

*Company outlets

Committees of Directors

Audit Committee

Mr. K. S. Shah, *Chairman*
 Mr. D. E. Udawadia
 Mr. Luigi Felice La Corte (Effective March 25, 2010)

Shareholders'/Investors' Grievance Committee

Mr. K. S. Shah, *Chairman*
 Mr. Anandh Balasundaram

Chief Financial Officer

Mr. Himanshu Agarwal (Effective May 03, 2011)

Company Secretary

Mr. N. R. Srinivasan

Annual General Meeting

at 3.00 PM. on Friday, July 22, 2011
 at The Ball Room, The Taj West End Hotel,
 Race Course Road, Bangalore 560 001

Notice

Notice is hereby given that the 32nd Annual General Meeting of the Members of AstraZeneca Pharma India Limited will be held at 3:00 P.M. on Friday, July 22, 2011 at The Ball Room, The Taj West End Hotel, Race Course Road, Bangalore 560 001, to transact the following business:

1. To receive, consider and adopt the audited Balance Sheet as at March 31, 2011 and the Profit and Loss Account for the financial year (15 months period) ended on that date and the Reports of the Directors and Auditors thereon.
2. To declare a Dividend.
3. To appoint a Director in place of Mr. D. E. Udwadia, who retires by rotation, and, being eligible, offers himself for re-appointment.
4. To appoint a Director in place of Mr. Ian Brimicombe, who retires by rotation, and, being eligible, offers himself for re-appointment.
5. To appoint M/s. BSR & Co., Chartered Accountants, as Statutory Auditors of the Company to hold office from the conclusion of this Meeting upto the conclusion of the next Annual General Meeting and to authorize the Board of Directors to fix their remuneration.
5. Members are requested to immediately notify change of address, if any, to the Company's Registrar & Share Transfer Agents, Integrated enterprises (India) Limited (earlier known as Alpha Systems Pvt. Ltd.), 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram, Bangalore 560003 (Telephone No. 080-23460815/6/7/8 Fax No. 080-23460819).
6. For the convenience of Members and for the proper conduct of the Meeting, entry to the place of Meeting will be regulated by an Attendance Slip, which is annexed to the Proxy Form. Members/Proxies attending the meeting are kindly requested to complete the enclosed Attendance Slip and affix their signature at the place provided thereon and hand it over at the entrance.
7. Members holding more than one Share Certificate in different folios are requested to kindly apply for consolidation of share folios and send the relative share certificates to the Company's Registrar & Share Transfer Agents. Members are requested to quote the Folio numbers / Client Id / DP Id in all correspondence.
8. Members are advised to avail of the Electronic Clearing Service (ECS) facility for dividends that may be declared. To avail of this facility, those members holding shares in physical form, are requested to return the duly filled in ECS form enclosed herewith to the Company's Registrar & Share Transfer Agents. Members holding shares in demat mode are requested to provide the details to NSDL and CDSL, as the case may be, through their respective Depository Participant (DP).

Notes

1. **A member entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote instead of himself / herself and such proxy need not be a member of the company.**
2. The relevant details as required by Clause 49 of the Listing Agreement executed with the Stock Exchanges, of persons seeking appointment / re-appointment as Directors under item nos. 3 and 4 are annexed.
3. The Register of Members and the Share Transfer Books of the Company shall remain closed from Saturday, July 09, 2011 to Friday, July 22, 2011 (both days inclusive).
4. The Dividend, if any, that may be declared at the Meeting will be paid on or before Saturday August 20, 2011 to those members entitled thereto whose names appear in the Register of Members of the Company at the close of business hours on Friday, July 08, 2011.
9. (a) Members may please note that unpaid or unclaimed Dividends in respect of the financial year upto 1993-94 have been transferred to the credit of the General Revenue Account of the Central Government in terms of Section 205A of the Companies Act, 1956. Members who have not encashed the dividend warrants for the aforesaid financial years are requested to claim the amount from the Registrar of Companies-Karnataka, Kendriya Sadan, 2nd Floor, 'E' Wing, Kormangala, Bangalore 560 034. Intimations have been sent to the Members concerned, pursuant to Rule 4A of the Companies Unpaid Dividend (Transfer to General Revenue Account of the Central Government) Rules, 1978.

(b) Members may also please note that consequent to the amendment to Section 205A (5) of the Act and the introduction of Section 205C by the Companies (Amendment) Act, 1999, all amounts transferred to the Unpaid Dividend Account of the Company for the years 1994-95, 1995-96, 1996-97, 1997-98, 1998-99, 1999-00, 2000-01, 2001(nine months) and 2002 remaining unpaid or unclaimed for a period of 7 (seven) years from the date of such transfer have been transferred to the Investor Education and Protection Fund.

10. Members are requested to note that as prescribed by the Securities and Exchange Board of India (SEBI), trading in securities of the Company is in dematerialised form only. Hence, Members who are yet to dematerialise their shares are advised to do so. The Company has entered into agreements with NSDL and CDSL for demat facilities.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

N R Srinivasan
Company Secretary

Place: Bangalore
Dated: May 13, 2011

Registered Office:
'Avishkar', Off Bellary Road
Hebbal, Bangalore - 560 024



Annexure to Notice

Details of the Directors seeking re-appointment at the 32nd Annual General Meeting

Particulars	Mr. D. E. Udawadia	Mr. Ian Brimicombe
Date of Birth	27 th September 1939	15 th October 1963
Date of Appointment	1 st June 1979	8 th September 2006
Qualifications	BA (Hons.), LL.B. Master's Degree in Political Science and History	B.Sc. Hons. King's College, London, Chartered Accountant (Institute of Chartered Accountants of England & Wales), Chartered Tax Adviser (Chartered Institute of Taxation)
Expertise in specific functional area	<p>Mr. Udawadia is a Solicitor and Advocate of the Bombay High Court and a Solicitor of the Supreme Court of England. Previously he was a partner of M/s Crawford Bayley & Co. Presently, he is partner of M/s. Udawadia & Udeshi, Solicitors & Advocates.</p> <p>Mr. Udawadia has been on the Board of the Company from inception, and since 8th September, 2000 as Chairman of the Board.</p> <p>He is also on the Board of various other companies.</p>	<p>Mr. Brimicombe is trained in audit, tax and corporate finance at Coopers & Lybrand, London (now Price Waterhouse Coopers) from 1986 to 1994, qualifying as a Chartered Accountant and a Chartered Tax Adviser. He has been Director of Group Tax, responsible for global tax operations and delivery of AstraZeneca's group tax targets. In January 2011 Mr. Brimicombe was given the additional responsibility over the treasury department, by becoming the group head of Tax and Treasury.</p>
Directorships held in other Public Companies (excluding foreign companies)	ABB Limited Bombay Burmah Trading Corp. Ltd. Development Credit Bank Ltd. Eureka Forbes Limited ITD Cementation India Ltd. JM Financial Limited JM Financial Consultants Private Limited JM Financial and Investment Consultancy Services Private Limited MPS Limited Mechanalysis (India) Ltd. Nitesh Estates Limited Wyeth Limited WABCO-TVS (INDIA) Limited	NIL

Particulars	Mr. D. E. Udhwadia	Mr. Ian Brimicombe
Membership/ Chairmanships of Committees of other public companies (included only Audit and Shareholders/ Investors Grievance Committee)	ABB Limited Audit Committee- Member Shareholders Grievance Committee- Chairman Bombay Burmah Trading Corporation Limited Audit Committee- Member Development Credit Bank Audit Committee- Member ITD Cementation India Ltd Audit Committee- Member MPS Limited Audit Committee- Member Nitesh Estates Limited Audit Committee- Member Wyeth Limited Audit Committee- Member WABCO-TVS (INDIA) Limited Audit Committee- Member	NIL
Shareholding in the Company (No. of shares)	NIL	NIL

In a world where there is increasing pressure on healthcare costs, AstraZeneca can be more effective if it can identify patients likely to benefit most from particular medicines.

Identifying the right treatment for the right patient at the right time and to embed it as part of routine clinical practice was the major challenge for Iressa. AstraZeneca worked with a variety of healthcare professionals (HCPs) to improve education and best practice in EGFR testing. Workshops involving pathologists, oncologists and respiratory physicians were run around the world to promote best practice and facilitate routine diagnostic testing.

Iressa is pioneering treatment of lung cancer, not just for the benefits it offers patients, but for the way in which it has brought together different groups of HCPs and changed the way patients are tested and treated as part of routine clinical practice.



**“ How do I
find a cancer
treatment that’s
right for me?**



Directors' Report

Your Directors have pleasure in presenting their 32nd Annual Report together with the Audited Accounts of the Company for the 15 Months period ended March 31, 2011.

Financial Results

(₹ in Mio)

Particulars	2010- 11 (15 months)*		2009
Sales and Other Income	6003		4024
Profit Before Tax	1010		884
Provision for Taxation			
- Income Tax	415	310	
- Adjustment for Deferred Tax	(46)	(6)	
- Fringe Benefit Tax	369	3	307
Profit after Taxation	641		577
Surplus brought forward from the previous year	948		409
Total amount available for appropriation	1589		986
Appropriation made by Directors			
Transfer to General Reserve	64		58
Transfer from Debenture Redemption Reserve	—		(312)
Appropriation recommended by Directors			
Dividend	250		250
Tax on proposed Dividend	40		42
Surplus carried over	1235		948

*Consequent to the change in the Accounting year of the Company from January-December' to 'April-March', the last accounting period was for a period of 15 months.

Distribution of Gross Revenue

